Overview
The Asia Pacific (APAC) region is one of the fastest growing markets for medical technology, driven by rising healthcare demand, aging populations, and increased investment in advanced devices.
The Global Market Model (GMM) estimates the APAC medical equipment market at $191.7 billion in 2024 measured in consumption value and projects it to grow at a 9.3% CAGR through 2029.
However, this growth story faces a significant headwind: rising tariffs and trade frictions. From diagnostic imaging equipment to surgical robotics and consumables, tariff escalations are inflating import costs, reshaping pricing dynamics, and directly influencing demand across APAC.
Why It Matters Now
Tariff increases on medical devices and components are putting additional pressure on procurement costs for suppliers and healthcare providers. Hospitals are being forced to delay equipment upgrades or restrict purchasing capacity, leading to knock-on effects on the pace of technology adoption. With APAC’s MedTech market expected to add nearly $90 billion in value between 2024 and 2029, these developments carry serious implications for the availability of advanced, life saving technologies in the region.
Why Tariffs in the US Still Affect APAC
Although tariff hikes are often framed as a US affordability issue, their effects cascade globally through interconnected supply chains. Many high value medical devices and components used in APAC are imported from the US and Europe. Tariffs raise costs at multiple stages of the chain, whether on finished devices or critical subcomponents such as sensors, semiconductors, and specialized metals.
Even when devices are assembled locally, higher global costs often flow through to APAC, where hospitals and patients ultimately face higher procurement prices. Since many healthcare systems in the region already operate under tight affordability constraints, even modest cost increases can result in delayed equipment adoption or reduced access to advanced technologies.
Impact on MedTech Supply Chains
The APAC diagnostic imaging equipment market is valued at $12.1 billion in 2024, growing at 5.2% CAGR through 2029. With much of this segment import dependent, tariff driven cost increases could pressure hospital budgets and influence adoption patterns. The APAC medical robots market is $3.7 billion in 2024 and is expanding at a rapid 20.6% CAGR. As most systems are manufactured outside the region, tariffs risk inflating prices, which may slow accessibility in cost sensitive markets. In vitro diagnostics, valued at $30.1 billion in 2024 and growing at 12.7%CAGR, is also vulnerable as tariffs on key inputs like reagents and components could raise procurement costs for laboratories and affect testing affordability. Hospital supplies, valued at $16.2 billion in 2024 and growing at 5.4% CAGR, may see higher operational costs for healthcare facilities where imported inputs are essential, even though many consumables are locally produced.
Explore our comprehensive market reports in the medtech industry
Strategies Companies Are Adopting
China is strengthening domestic innovation and implementing government backed policies to reduce reliance on imported US and EU medical devices. India is rolling out incentive schemes and building medical device parks to expand local MedTech manufacturing. Southeast Asian countries such as Thailand, Malaysia, and Vietnam are gaining attention as potential alternatives for companies looking to diversify supply chains, supported by policy initiatives and existing manufacturing strengths.
Challenges and Considerations
Relocating manufacturing capacity or building new facilities is expensive and resource intensive, while navigating the varied regulatory frameworks across APAC adds another layer of complexity. Localising production may also require sharing sensitive intellectual property, which is a concern for many multinational MedTech companies.
Outlook
Even with tariffs in place, APAC’s MedTech market will remain strong, led by high growth segments such as medical robots growing at 20.6% and in vitro diagnostics growing at 12.7%. Tariffs, however, will act as a filter, favoring companies that proactively invest in localisation, dual sourcing, and supply chain redesigns.
